Stephen Locarnini，墨尔本，澳大利亚——HBV相关实验室及人物

bigben446

Stephen Locarnini，墨尔本，澳大利亚——HBV相关实验室及人物介绍系列

Stephen Locarnini，墨尔本，澳大利亚
研究肝炎病毒的常青树

Revill, P. A. and S. A. Locarnini (2016). "New perspectives on the hepatitis B virus life cycle in the human liver." J Clin Invest 126(3): 833-6.
Locarnini, S. and D. S. Chen, et al. (2016). "No more excuses: viral hepatitis can be eliminated." Lancet 387(10029): 1703-4.
Littlejohn, M. and S. Locarnini, et al. (2016). "Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus." Cold Spring Harb Perspect Med 6(1): a021360.
Sarin, S. K. and M. Kumar, et al. (2016). "Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update." Hepatol Int 10(1): 1-98.
Wallace, J. and M. Pitts, et al. (2016). "Essential components in developing public policy to control viral hepatitis: lessons from Taiwan." Hepatol Int 10(2): 355-62.
Rybczynska, J. and K. Campbell, et al. (2016). "CD4+ T Cells Are Not Required for Suppression of Hepatitis B Virus Replication in the Liver of Vaccinated Chimpanzees." J Infect Dis 213(1): 49-56.
Revill, P. and S. Locarnini (2015). "Viral factors and predicting disease outcomes in chronic hepatitis B." Gut 64(2): 191-3.
Zhou, B. and H. Dong, et al. (2015). "Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy." Sci Rep 5: 17123.
Hyakumura, M. and R. Walsh, et al. (2015). "Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity." J Virol 89(22): 11312-22.
Liang, T. J. and T. M. Block, et al. (2015). "Present and future therapies of hepatitis B: From discovery to cure." Hepatology 62(6): 1893-908.
Gish, R. G. and M. F. Yuen, et al. (2015). "Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent." Antiviral Res 121: 97-108.
MacLachlan, J. H. and S. Locarnini, et al. (2015). "Estimating the global prevalence of hepatitis B." Lancet 386(10003): 1515-7.
Gish, R. G. and B. D. Given, et al. (2015). "Chronic hepatitis B: Virology, natural history, current management and a glimpse  at future opportunities." Antiviral Res 121: 47-58.
Locarnini, S. and A. Hatzakis, et al. (2015). "Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs." J Hepatol 62(1 Suppl): S76-86.
Bowden, S. and S. Locarnini, et al. (2015). "Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine." World J Gastroenterol 21(15): 4644-51.
Giles, M. and K. Visvanathan, et al. (2015). "Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B." Gut 64(11): 1810-5.
Warner, N. and S. Locarnini (2014). "Mechanisms of hepatitis B virus resistance development." Intervirology 57(3-4): 218-24.
Han, M. and M. Littlejohn, et al. (2014). "Molecular epidemiology of hepatitis delta virus in the Western Pacific region." J Clin Virol 61(1): 34-9.
Bowden, F. J. and B. J. Currie, et al. (2014). "Should Aboriginals in the "Top End" of the Northern Territory be vaccinated against hepatitis A? 1994." Med J Aust 200(11): 678-9.
Lesmana, C. R. and K. Jackson, et al. (2014). "Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patients." United European Gastroenterol J 2(2): 99-107.
Jegaskanda, S. and S. H. Ahn, et al. (2014). "Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen." J Virol 88(18): 10412-20.
Beard, M. R. and R. Ffrench, et al. (2014). "A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses." Gastroenterology 147(1): e1-4.
Locarnini, S. and D. Shouval (2014). "Commonly found variations/mutations in the HBsAg of hepatitis B virus in the context of effective immunization programs: questionable clinical and public health significance." J Virol 88(11): 6532.
Greenup, A. J. and P. K. Tan, et al. (2014). "Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus." J Hepatol 61(3): 502-7.
Gish, R. G. and J. A. Gutierrez, et al. (2014). "A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation." J Viral Hepat 21(12): 905-8.
Littlejohn, M. and J. Davies, et al. (2014). "Molecular virology of hepatitis B virus, sub-genotype C4 in northern Australian Indigenous populations." J Med Virol 86(4): 695-706.
Ayres, A. and L. Yuen, et al. (2014). "Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations." J Viral Hepat 21(11): 809-17.
Croagh, C. M. and S. J. Bell, et al. (2013). "Longitudinal observation of viral load changes in untreated HBeAg negative chronic hepatitis B." Acta Gastroenterol Belg 76(3): 275-81.
Devi, U. and S. Locarnini (2013). "Hepatitis B antivirals and resistance." Curr Opin Virol 3(5): 495-500.
Locarnini, S. and M. Littlejohn, et al. (2013). "Possible origins and evolution of the hepatitis B virus (HBV)." Semin Cancer Biol 23(6 Pt B): 561-75.
Chen, D. S. and S. Locarnini, et al. (2013). "Report from a Viral Hepatitis Policy Forum on implementing the WHO Framework for  Global Action on viral hepatitis in North Asia." J Hepatol 59(5): 1073-80.
Bayliss, J. and L. Lim, et al. (2013). "Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma." J Hepatol 59(5): 1022-8.
Locarnini, S. and A. Thompson (2013). "Current perspectives on chronic hepatitis B." Semin Liver Dis 33(2): 95-6.
Li, W. and N. Warner, et al. (2013). "Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype." Hepatol Int 7(2): 443-50.
Matthews, G. V. and R. J. Ali, et al. (2013). "Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation  of HAART in HIV-HBV coinfected individuals." PLoS One 8(4): e61297.
Davies, J. and M. Littlejohn, et al. (2013). "Molecular epidemiology of hepatitis B in the Indigenous people of northern Australia." J Gastroenterol Hepatol 28(7): 1234-41.
Warner, N. and S. Locarnini (2013). "The new front-line in hepatitis B/D research: identification and blocking of a functional receptor." Hepatology 58(1): 9-12.
Matthews, G. V. and E. C. Seaberg, et al. (2013). "Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus." Clin Infect Dis 56(9): e87-94.
Zoulim, F. and S. Locarnini (2013). "Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance." Liver Int 33 Suppl 1: 116-24.
Cheng, Y. and S. Guindon, et al. (2013). "Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion." Gut 62(9): 1347-55.
Cabuang, L. M. and T. Shaw, et al. (2012). "In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection." J Med Virol 84(8): 1166-76.
Liaw, Y. F. and J. H. Kao, et al. (2012). "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update." Hepatol Int 6(3): 531-61.
Dandri, M. and S. Locarnini (2012). "New insight in the pathobiology of hepatitis B virus infection." Gut 61 Suppl 1: i6-17.
Locarnini, S. and S. Bowden (2012). "Hepatitis B surface antigen quantification: not what it seems on the surface." Hepatology 56(2): 411-4.
Gish, R. and J. D. Jia, et al. (2012). "Selection of chronic hepatitis B therapy with high barrier to resistance." Lancet Infect Dis 12(4): 341-53.
Zoulim, F. and S. Locarnini (2012). "Management of treatment failure in chronic hepatitis B." J Hepatol 56 Suppl 1: S112-22.
Cheong, W. S. and M. Hyakumura, et al. (2012). "Modulation of the immunogenicity of virus-like particles composed of mutant hepatitis B virus envelope subunits." Antiviral Res 93(2): 209-18.
Desmond, C. P. and S. Gaudieri, et al. (2012). "Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease." J Virol 86(2): 1181-92.
Wong, V. W. and G. L. Wong, et al. (2012). "Antiviral drug resistance testing in patients with chronic hepatitis B." Dig Dis Sci 57(1): 221-31.
Croagh, C. M. and S. J. Bell, et al. (2012). "Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing." Intern Med J 42(2): 170-5.
Liaw, Y. F. and J. H. Kao, et al. (2012). "Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update." Hepatol Int 6(4): 809-10.
Walsh, R. and S. Locarnini (2012). "Hepatitis B precore protein: pathogenic potential and therapeutic promise." Yonsei Med J 53(5): 875-85.
Wilson, R. and N. Warner, et al. (2011). "The hepatitis B e antigen suppresses IL-1beta-mediated NF-kappaB activation in hepatocytes." J Viral Hepat 18(10): e499-507.
Venegas, M. and M. V. Alvarado-Mora, et al. (2011). "Phylogenetic analysis of hepatitis B virus genotype F complete genome sequences from Chilean patients with chronic infection." J Med Virol 83(9): 1530-6.
Chan, H. L. and A. Thompson, et al. (2011). "Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report." J Hepatol 55(5): 1121-31.
Lang, T. and C. Lo, et al. (2011). "The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway." J Hepatol 55(4): 762-9.
Halfon, P. and S. Locarnini (2011). "Hepatitis C virus resistance to protease inhibitors." J Hepatol 55(1): 192-206.
Walsh, R. and S. Nuttall, et al. (2011). "Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody." Virology 411(1): 132-41.
Patterson, S. J. and J. George, et al. (2011). "Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B." Gut 60(2): 247-54.
Ahn, S. H. and L. Yuen, et al. (2010). "Molecular and clinical characteristics of hepatitis B virus in Korea." J Med Virol 82(7): 1126-34.
Thompson, A. J. and T. Nguyen, et al. (2010). "Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers." Hepatology 51(6): 1933-44.
Croagh, C. M. and S. J. Bell, et al. (2010). "Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B." Liver Int 30(8): 1115-22.
Locarnini, S. (2010). "Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management." J Gastroenterol Hepatol 25(4): 649-51.
Clements, C. J. and B. Coghlan, et al. (2010). "Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?" Bull World Health Organ 88(1): 66-73.
Iser, D. M. and N. Warner, et al. (2010). "Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen." J Virol 84(12): 5860-7.
Nguyen, T. and A. J. Thompson, et al. (2010). "Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia." J Hepatol 52(4): 508-13.
Crane, M. and S. Sirivichayakul, et al. (2010). "No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy." J Virol 84(6): 2657-65.
Damerow, H. and L. Yuen, et al. (2010). "Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern." J Med Virol 82(11): 1850-8.
Mendes-Correa, M. C. and J. R. Pinho, et al. (2010). "High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B." J Med Virol 82(9): 1481-8.
Audsley, J. and N. Arrifin, et al. (2009). "Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals  does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations." HIV Med 10(4): 229-35.
Yuen, L. K. and S. A. Locarnini (2009). "Genetic variability of hepatitis B virus and response to antiviral treatments: searching for a bigger picture." J Hepatol 50(3): 445-8.
Lewin, S. R. and R. M. Ribeiro, et al. (2009). "Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy." Hepatology 49(4): 1113-21.
Thompson, A. J. and D. Colledge, et al. (2009). "Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro." Antivir Ther 14(6): 797-808.
Nguyen, T. and S. Locarnini (2009). "Hepatitis: Monitoring drug therapy for hepatitis B--a global challenge?" Nat Rev Gastroenterol Hepatol 6(10): 565-7.
Nguyen, T. and P. Desmond, et al. (2009). "The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B." Hepatol Int 3(Suppl 1): 5-15.
Zoulim, F. and S. Locarnini (2009). "Hepatitis B virus resistance to nucleos(t)ide analogues." Gastroenterology 137(5): 1593-608.e1-2.
Eyre, N. S. and R. J. Phillips, et al. (2009). "Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells." J Hepatol 51(3): 446-57.
Warner, N. and S. Locarnini (2009). "Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?" Antivir Ther 14(2): 139-42.
Chang, J. J. and S. Sirivichayakul, et al. (2009). "Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection." J Virol 83(15): 7649-58.
Wiseman, E. and M. A. Fraser, et al. (2009). "Perinatal transmission of hepatitis B virus: an Australian experience." Med J Aust 190(9): 489-92.
Kamili, S. and V. Sozzi, et al. (2009). "Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model." Hepatology 49(5): 1483-91.
Nguyen, T. and S. Locarnini, et al. (2008). "Changing landscape of antiviral resistance management in chronic hepatitis B." J Gastroenterol Hepatol 23(9): 1314-7.
Raimondo, G. and J. P. Allain, et al. (2008). "Statements from the Taormina expert meeting on occult hepatitis B virus infection." J Hepatol 49(4): 652-7.
Matthews, G. V. and A. Avihingsanon, et al. (2008). "A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand." Hepatology 48(4): 1062-9.
Preiss, S. and M. Littlejohn, et al. (2008). "Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance." Hepatology 48(3): 741-9.
Warner, N. and S. Locarnini (2008). "The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound." Hepatology 48(1): 88-98.
Poustchi, H. and A. Mohamadkhani, et al. (2008). "Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease." J Viral Hepat 15(10): 753-60.
Pawlotsky, J. M. and G. Dusheiko, et al. (2008). "Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach." Gastroenterology 134(2): 405-15.
Sung, J. J. and S. K. Tsui, et al. (2008). "Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus." J Virol 82(7): 3604-11.
Hui, C. K. and H. Y. Zhang, et al. (2008). "96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B." J Hepatol 48(5): 714-20.
Liaw, Y. F. and N. Leung, et al. (2008). "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update." Hepatol Int 2(3): 263-83.
Heipertz, R. J. and T. G. Miller, et al. (2007). "In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication." J Virol 81(7): 3068-76.
Yuen, L. K. and A. Ayres, et al. (2007). "SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B." Antiviral Res 75(1): 64-74.
Visvanathan, K. and N. A. Skinner, et al. (2007). "Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein." Hepatology 45(1): 102-10.
Locarnini, S. and N. Warner (2007). "Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV." Antivir Ther 12 Suppl 3: H15-23.
Sheldon, J. and B. Ramos, et al. (2007). "Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity." J Acquir Immune Defic Syndr 46(3): 279-82.
Chang, J. J. and A. J. Thompson, et al. (2007). "The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection." Hepatology 46(5): 1332-40.
Thompson, A. and S. Locarnini, et al. (2007). "The natural history and the staging of chronic hepatitis B: time for reevaluation of the virus-host relationship based on molecular virology and immunopathogenesis considerations?" Gastroenterology 133(3): 1031-5.
Revill, P. A. and M. Littlejohn, et al. (2007). "Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals." AIDS 21(13): 1701-10.
Thompson, A. J. and A. Ayres, et al. (2007). "Lamivudine resistance in patients with chronic hepatitis B: role of clinical and  virological factors." J Gastroenterol Hepatol 22(7): 1078-85.
Warner, N. and S. Locarnini, et al. (2007). "The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro." Antimicrob Agents Chemother 51(7): 2285-92.
Sasadeusz, J. J. and S. L. Locarnini, et al. (2007). "Why do we not yet have combination chemotherapy for chronic hepatitis B?" Med J Aust 186(4): 204-6.
Riordan, S. M. and N. A. Skinner, et al. (2006). "Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury." Inflamm Res 55(7): 279-85.
Riordan, S. M. and N. Skinner, et al. (2006). "Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B." Clin Vaccine Immunol 13(8): 972-4.
Hui, C. K. and S. Bowden, et al. (2006). "Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy." J Clin Microbiol 44(8): 2983-7.
Gish, R. G. and S. A. Locarnini (2006). "Chronic hepatitis B: current testing strategies." Clin Gastroenterol Hepatol 4(6): 666-76.
Lim, S. G. and C. T. Wai, et al. (2006). "A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B." Antivir Ther 11(2): 245-53.
Bartholomeusz, A. and S. Locarnini (2006). "Hepatitis B virus mutations associated with antiviral therapy." J Med Virol 78 Suppl 1: S52-5.
Locarnini, S. and T. Shaw, et al. (2005). "Cellular response to conditional expression of the hepatitis B virus precore and  core proteins in cultured hepatoma (Huh-7) cells." J Clin Virol 32(2): 113-21.
Sheldon, J. and N. Camino, et al. (2005). "Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir." Antivir Ther 10(6): 727-34.
Locarnini, S. (2005). "Hepatitis C and hepatitis E vaccines: research update." Med J Malaysia 60 Suppl B: 116-24.
Locarnini, S. (2005). "Interpretation and application of virological testing including resistance in chronic hepatitis B." Med J Malaysia 60 Suppl B: 41-51.
Sung, J. J. and M. L. Wong, et al. (2005). "Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor  of sustained response to therapy." Gastroenterology 128(7): 1890-7.
Chan, H. L. and S. K. Tsui, et al. (2005). "Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C." J Infect Dis 191(12): 2022-32.
Locarnini, S. (2005). "Therapies for hepatitis B: where to from here?" Gastroenterology 128(3): 789-92.
Hui, C. K. and J. Yu, et al. (2005). "Sexual transmission of hepatitis B infection despite the presence of hepatitis B  virus immunity in recipients of allogeneic bone marrow transplantation." J Clin Virol 32(2): 173-8.
Bell, S. J. and A. Lau, et al. (2005). "Chronic hepatitis B: recommendations for therapy based on the natural history of  disease in Australian patients." J Clin Virol 32(2): 122-7.
Shaw, T. and S. Locarnini (2004). "Entecavir for the treatment of chronic hepatitis B." Expert Rev Anti Infect Ther 2(6): 853-71.
Norder, H. and A. M. Courouce, et al. (2004). "Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes." Intervirology 47(6): 289-309.
Werle-Lapostolle, B. and S. Bowden, et al. (2004). "Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy." Gastroenterology 126(7): 1750-8.
Locarnini, S. and A. Hatzakis, et al. (2004). "Management of antiviral resistance in patients with chronic hepatitis B." Antivir Ther 9(5): 679-93.
Angus, P. and S. Locarnini (2004). "Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!." Antivir Ther 9(2): 145-8.
Lee, J. Y. and S. Locarnini (2004). "Hepatitis B virus: pathogenesis, viral intermediates, and viral replication." Clin Liver Dis 8(2): 301-20.
Gish, R. G. and S. Locarnini (2004). "Studying the treatment of chronic hepatitis B viral infection in special populations." Methods Mol Med 96: 465-98.
Tenney, D. J. and S. M. Levine, et al. (2004). "Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine." Antimicrob Agents Chemother 48(9): 3498-507.
Beard, M. R. and S. Locarnini (2004). "Monitoring gene expression using DNA microarrays during hepatitis B virus infection." Methods Mol Med 96: 55-64.
Wightman, F. and T. Walters, et al. (2004). "Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains." J Clin Microbiol 42(8): 3809-12.
Zanati, S. A. and S. A. Locarnini, et al. (2004). "Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated  with prednisolone and chloroquine." J Clin Virol 31(1): 53-7.
Shaw, T. and S. Bowden, et al. (2004). "Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?" Gastroenterology 126(1): 343-7.
Basuni, A. A. and L. Butterworth, et al. (2004). "Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries." Vaccine 22(21-22): 2791-9.
Jazayeri, M. S. and A. A. Basuni, et al. (2004). "Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific region." J Hepatol 41(1): 139-46.
Locarnini, S. (2004). "Molecular virology of hepatitis B virus." Semin Liver Dis 24 Suppl 1: 3-10.
Chin, R. and S. Locarnini (2003). "Treatment of chronic hepatitis B: current challenges and future directions." Rev Med Virol 13(4): 255-72.
Tallis, G. F. and G. M. Ryan, et al. (2003). "Evidence of patient-to-patient transmission of hepatitis C virus through contaminated intravenous anaesthetic ampoules." J Viral Hepat 10(3): 234-9.
Chen, R. Y. and S. Bowden, et al. (2003). "Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus." J Gastroenterol Hepatol 18(6): 630-7.
Ayres, A. and A. Bartholomeusz, et al. (2003). "Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure." J Clin Virol 27(1): 111-6.
Locarnini, S. and J. McMillan, et al. (2003). "The hepatitis B virus and common mutants." Semin Liver Dis 23(1): 5-20.
Locarnini, S. (2003). "Hepatitis B viral resistance: mechanisms and diagnosis." J Hepatol 39 Suppl 1: S124-32.
Feld, J. and J. Y. Lee, et al. (2003). "New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B." Hepatology 38(3): 545-53.
Schilling, R. and S. Ijaz, et al. (2003). "Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions." J Virol 77(16): 8882-92.
Cooley, L. and A. Ayres, et al. (2003). "Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals." AIDS 17(11): 1649-57.
Klein, C. and C. T. Bock, et al. (2003). "Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA." Gastroenterology 125(1): 9-18.
Lau, G. K. and M. L. He, et al. (2002). "Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation." Hepatology 36(3): 702-9.
Delaney, W. T. and R. Edwards, et al. (2002). "Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro." Antimicrob Agents Chemother 46(9): 3057-60.
Torresi, J. and L. Earnest-Silveira, et al. (2002). "Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene." Virology 299(1): 88-99.
Sievert, W. and S. Pianko, et al. (2002). "Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major." Am J Gastroenterol 97(4): 982-7.
Locarnini, S. A. and A. Bartholomeusz (2002). "Advances in hepatitis C: what is coming in the next 5 years?" J Gastroenterol Hepatol 17(4): 442-7.
Torresi, J. and L. Earnest-Silveira, et al. (2002). "Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy." Virology 293(2): 305-13.
Bock, C. T. and H. L. Tillmann, et al. (2002). "Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation." Gastroenterology 122(2): 264-73.
Chen, R. Y. and P. V. Desmond, et al. (2002). "Emerging therapies of hepatitis B and C." J Gastroenterol Hepatol 17 Suppl: S471-81.
Delaney, W. T. and A. Bartholomeusz, et al. (2002). "Evolving therapies for the treatment of chronic hepatitis B virus infection." Expert Opin Investig Drugs 11(2): 169-87.
Locarnini, S. A. (2002). "Mechanisms of drug resistance and novel approaches to therapy for chronic hepatitis C." J Gastroenterol Hepatol 17 Suppl 3: S351-9.
Locarnini, S. A. (2002). "Clinical relevance of viral dynamics and genotypes in hepatitis B virus." J Gastroenterol Hepatol 17 Suppl 3: S322-8.
Shaw, T. and S. Bowden, et al. (2002). "Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints." Gastroenterology 123(6): 2135-40.
Feld, J. and S. Locarnini (2002). "Antiviral therapy for hepatitis B virus infections: new targets and technical challenges." J Clin Virol 25(3): 267-83.
Bonacini, M. and A. Kurz, et al. (2002). "Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV." Gastroenterology 122(1): 244-5.
Lok, A. S. and F. Zoulim, et al. (2002). "Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay." J Clin Microbiol 40(10): 3729-34.
Lewin, S. and T. Walters, et al. (2002). "Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies." Antiviral Res 55(3): 381-96.
Delaney, W. T. and R. Edwards, et al. (2001). "Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus." Antimicrob Agents Chemother 45(6): 1705-13.
Bock, C. T. and S. Schwinn, et al. (2001). "Structural organization of the hepatitis B virus minichromosome." J Mol Biol 307(1): 183-96.
Stuyver, L. J. and S. A. Locarnini, et al. (2001). "Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region." Hepatology 33(3): 751-7.
Lewin, S. R. and R. M. Ribeiro, et al. (2001). "Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed." Hepatology 34(5): 1012-20.
Colonno, R. J. and E. V. Genovesi, et al. (2001). "Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection." J Infect Dis 184(10): 1236-45.
Chin, R. and T. Shaw, et al. (2001). "In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil." Antimicrob Agents Chemother 45(9): 2495-501.
Bartholomeusz, A. and S. Locarnini (2001). "Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype." Hepatology 34(2): 432-5.
Lee, J. Y. and J. G. Culvenor, et al. (2001). "Duck hepatitis B virus replication in primary bile duct epithelial cells." J Virol 75(16): 7651-61.
Delaney, W. T. and S. Locarnini, et al. (2001). "Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation." Antivir Chem Chemother 12(1): 1-35.
Locarnini, S. (2000). "Molecular pathogenesis of viral hepatitis." J Gastroenterol Hepatol 15 Suppl: G46-8.
Shaw, T. and S. Locarnini (2000). "Combination chemotherapy for hepatitis B virus: the path forward?" Drugs 60(3): 517-31.
Torresi, J. and S. Locarnini (2000). "Antiviral chemotherapy for the treatment of hepatitis B virus infections." Gastroenterology 118(2 Suppl 1): S83-103.
Shaw, T. and S. Locarnini (2000). "Combination chemotherapy for hepatitis B virus: the final solution?" Hepatology 32(2): 430-2.
Wilson, N. and T. A. Ruff, et al. (2000). "The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu." Vaccine 18(26): 3059-66.
Nicoll, A. and S. Locarnini, et al. (2000). "Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo." J Gastroenterol Hepatol 15(3): 304-10.
Shaw, T. and S. A. Locarnini (2000). "Assays for Hepatitis B Virus DNA-and RNA-Dependent DNA Polymerase Activities." Methods Mol Med 24: 87-95.
McCaughan, G. W. and J. Spencer, et al. (1999). "Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of  recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin." Liver Transpl Surg 5(6): 512-9.
Torresi, J. and F. Li, et al. (1999). "Only the non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells." J Gen Virol 80 ( Pt 5): 1185-8.
Bowden, S. and S. Locarnini (1999). "TT virus: an agent of transfusion-associated hepatitis or yellow herring?" J Gastroenterol Hepatol 14(4): 299-300.
Locarnini, S. and C. Birch (1999). "Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients." J Hepatol 30(3): 536-50.
Lau, G. K. and W. F. Carman, et al. (1999). "Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective." J Gastroenterol Hepatol 14(1): 3-12.
Hardikar, W. and L. D. Moaven, et al. (1999). "Hepatitis G: viroprevalence and seroconversion in a high-risk group of children." J Viral Hepat 6(4): 337-41.
Shaw, T. and S. A. Locarnini (1999). "Preclinical aspects of lamivudine and famciclovir against hepatitis B virus." J Viral Hepat 6(2): 89-106.
Torresi, J. and S. A. Locarnini (1999). "New therapeutic strategies in the treatment of hepatitis B virus infection." Expert Opin Investig Drugs 8(3): 289-305.
Chin, R. and S. Locarnini (1998). "New therapies for the treatment of chronic hepatitis B infection." Curr Opin Infect Dis 11(6): 719-26.
Littlejohn, M. and S. Locarnini, et al. (1998). "Targets for inhibition of hepatitis C virus replication." Antivir Ther 3(Suppl 3): 83-91.
Nicoll, A. J. and D. L. Colledge, et al. (1998). "Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue." Antimicrob Agents Chemother 42(12): 3130-5.
de Man, R. A. and A. I. Bartholomeusz, et al. (1998). "The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss." J Hepatol 29(4): 669-75.
Lin, E. and C. Luscombe, et al. (1998). "Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo." Antimicrob Agents Chemother 42(8): 2132-7.
Ostapowicz, G. and K. J. Watson, et al. (1998). "Role of alcohol in the progression of liver disease caused by hepatitis C virus infection." Hepatology 27(6): 1730-5.
Locarnini, S. A. (1998). "Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance." Hepatology 27(1): 294-7.
Torresi, J. and J. Meanger, et al. (1997). "High level expression of the capsid protein of hepatitis E virus in diverse eukaryotic cells using the Semliki Forest virus replicon." J Virol Methods 69(1-2): 81-91.
Nicoll, A. and S. Locarnini (1997). "Review: Present and future directions in the treatment of chronic hepatitis B infection." J Gastroenterol Hepatol 12(12): 843-54.
Bartholomeusz, A. and L. C. Groenen, et al. (1997). "Clinical experience with famciclovir against hepatitis B virus." Intervirology 40(5-6): 337-42.
Li, F. and J. Torresi, et al. (1997). "Amino-terminal epitopes are exposed when full-length open reading frame 2 of hepatitis E virus is expressed in Escherichia coli, but carboxy-terminal epitopes are masked." J Med Virol 52(3): 289-300.
Aye, T. T. and A. Bartholomeusz, et al. (1997). "Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation." J Hepatol 26(5): 1148-53.
Locarnini, S. A. and J. E. Newbold (1997). "Chronic hepatitis B: the therapeutic challenge." J Antimicrob Chemother 39(5): 559-62.
Nicoll, A. J. and P. W. Angus, et al. (1997). "Demonstration of duck hepatitis B virus in bile duct epithelial cells: implications for pathogenesis and persistent infection." Hepatology 25(2): 463-9.
McMillan, J. S. and D. S. Bowden, et al. (1996). "Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation." Hepatology 24(6): 1371-8.
McCaughan, G. and P. Angus, et al. (1996). "Retransplantation for precore mutant-related chronic hepatitis B infection: prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy." Liver Transpl Surg 2(6): 472-4.
Shaw, T. and S. S. Mok, et al. (1996). "Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir." Hepatology 24(5): 996-1002.
Luscombe, C. and J. Pedersen, et al. (1996). "Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression." Hepatology 24(4): 766-73.
Civitico, G. and T. Shaw, et al. (1996). "Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro." Antimicrob Agents Chemother 40(5): 1180-5.
Lin, E. and C. Luscombe, et al. (1996). "The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo." Antimicrob Agents Chemother 40(2): 413-18.
Bowden, D. S. and L. D. Moaven, et al. (1996). "New hepatitis viruses: are there enough letters in the alphabet?" Med J Aust 164(2): 87-9.
McMillan, J. S. and T. Shaw, et al. (1995). "Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro." Hepatology 22(1): 36-43.
Dean, J. and S. Bowden, et al. (1995). "Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir." Antiviral Res 27(1-2): 171-8.
Wang, Y. and C. Luscombe, et al. (1995). "Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid." Antimicrob Agents Chemother 39(2): 556-8.
Angus, P. W. and S. A. Locarnini, et al. (1995). "Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation." Hepatology 21(1): 14-8.
Shaw, T. and S. A. Locarnini (1995). "Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis." Liver 15(4): 169-84.
Li, F. and H. Zhuang, et al. (1994). "Persistent and transient antibody responses to hepatitis E virus detected by western immunoblot using open reading frame 2 and 3 and glutathione S-transferase fusion proteins." J Clin Microbiol 32(9): 2060-6.
Civitico, G. M. and S. A. Locarnini (1994). "The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected  primary hepatocyte cultures." Virology 203(1): 81-9.
Luscombe, C. and J. Pedersen, et al. (1994). "Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy." Liver 14(4): 182-92.
Shaw, T. and P. Amor, et al. (1994). "In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus." Antimicrob Agents Chemother 38(4): 719-23.
Angus, P. and M. Richards, et al. (1993). "Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection." J Gastroenterol Hepatol 8(4): 353-7.
Niu, J. and Y. Wang, et al. (1993). "The use of ampligen alone and in combination with ganciclovir and coumermycin A1  for the treatment of ducks congenitally-infected with duck hepatitis B virus." Antiviral Res 21(2): 155-71.
Locarnini, S. (1991). "Design of new anti-viral agents for chronic hepatitis B virus infection." J Gastroenterol Hepatol 6 Suppl 1: 18-22.
Niu, J. Z. and Y. Y. Wang, et al. (1990). "Effect of Phyllanthus amarus on duck hepatitis B virus replication in vivo." J Med Virol 32(4): 212-8.
Bishop, N. and G. Civitico, et al. (1990). "Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of  an in vitro system using the duck hepatitis B virus model." J Med Virol 31(2): 82-9.
Civitico, G. and Y. Y. Wang, et al. (1990). "Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds." J Med Virol 31(2): 90-7.
Zhuang, H. and A. G. Coulepis, et al. (1983). "Characterization of a precipitating antigen detected in the serum of patients with viral hepatitis." J Med Virol 11(4): 267-76.
Zhuang, H. and A. G. Coulepis, et al. (1982). "Detection of markers of hepatitis B infection in serum dried on to filter-paper:  an application to field studies." Bull World Health Organ 60(5): 783-7.
Pedersen, J. S. and B. H. Toh, et al. (1981). "Autoantibody to intermediate filaments in viral hepatitis." Clin Immunol Immunopathol 21(2): 154-61.